|
1
|
Arias IM, Alter HJ, Boyer JL, Cohen DE,
Shafritz DA, Thorgeirsson SS and Wolkoff AW: The Liver: Biology and
Pathobiology. 6th edition. Wiley-Blackwell, Hoboken, NJ,
2020.
|
|
2
|
Pan F, Huang Q and Li X: Classification of
liver tumors with CEUS based on 3D-CNN. In: 2019 IEEE 4th
international conference on advanced robotics and mechatronics
(ICARM). IEEE 845-849, 2019.
|
|
3
|
Wang ZG, He ZY, Chen YY, Gao H and Du XL:
Incidence and survival outcomes of secondary liver cancer: A
surveillance epidemiology and end results database analysis. Transl
Cancer Res. 10:1273–1283. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shannon AH, Ruff SM and Pawlik TM: Expert
insights on current treatments for hepatocellular carcinoma.
Clinical and molecular approaches and bottlenecks to progress. J
Hepatocell Carcinoma. 9:1247–1261. 2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Rashed WM, Kandeil MAM, Mahmoud MO and
Ezzat S: Hepatocellular carcinoma (HCC) in Egypt. A comprehensive
overview. J Egypt Natl Can Inst. 32(5)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Piñero FF, Dirchwolf M and Pessôa MG:
Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and
treatment response assessment. Cells. 9(1370)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Jahnke G, Smidla J and Poczai P:
MolMarker: A simple tool for DNA fingerprinting studies and
polymorphic information content calculation. Diversity.
14(497)2022.
|
|
8
|
Al-Samarai FR and Al-Kazaz AA: Molecular
markers: An introduction and applications. Eur J Mol Biotechnol.
9:118–130. 2015.
|
|
9
|
Senthil N and Gurusubramanian G: Random
amplified polymorphic DNA (RAPD) markers and its applications. Sci
Vis. 11:116–124. 2011.
|
|
10
|
Allami ZZG and Dragh MA: Identification of
some breast cancer related genes by RAPD technique in Maysan
Province Iraq. Revis Bionatura. 7:20–28. 2022.
|
|
11
|
El-Far M, Abol-Enein H, Zakaria A and
El-Gedamy M: Detection of genomic instability in renal cancer by
random amplified polymorphic DNA analysis from urine samples as a
non-invasive method: Potential use in diagnosis. Cancer Sci Res.
1(7)2013.
|
|
12
|
Xian ZH, Cong WM, Zhang SH and Wu MC:
Genetic alterations of hepatocellular carcinoma by random amplified
polymorphic DNA analysis and cloning sequencing of tumor
differential DNA fragment. World J Gastroenterol. 11:4102–4107.
2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
El-Far M, Abol-Enein H, Zakaria A and
El-Gedamy M: Application of random amplified polymorphic DNA-PCR
technique in early diagnosis of bladder cancer using urine samples.
Curr Top Bio Res. 15:23–34. 2013.
|
|
14
|
Ibrahim MA, Saleh NA, Archoukieh E,
Al-Obaide HW, Al-Obaidi MM and Said HM: Detection of novel genomic
polymorphism in acute lymphoblastic leukemia by random amplified
polymorphic DNA analysis. Int J Cancer Res. 6:19–26. 2010.
|
|
15
|
Zakaria A and Mahmoud AZ: Molecular
characterization of TP53 gene mutations in human bladder cancer.
Pharm Biotechnol. Curr Res. 2:1–7. 2017.
|
|
16
|
Armitage P, Berry G and Matthews JNS:
Statistical Methods in Medical Research. 4th edition.
Wiley-Blackwell, Hoboken, NJ, 2002.
|
|
17
|
Bale R, Schullian P, Eberle G, Putzer D,
Zoller H, Schneeberger S, Manzl C, Moser P and Oberhuber G:
Stereotactic radiofrequency ablation of hepatocellular carcinoma: A
histopathological study in explanted livers. Hepatology.
70:840–850. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Suresh D, Srinivas AN and Kumar DP:
Etiology of hepatocellular carcinoma: Special focus on fatty liver
disease. Front Oncol. 10(601710)2020.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Loy LM, Low HM, Choi JY, Rhee H, Wong CF
and Tan CH: Variant hepatocellular carcinoma subtypes according to
the 2019 WHO classification: An imaging-focused review. AJR Am J
Roentgenol. 219:212–223. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Martins-Filho SN, Paiva C, Azevedo RS and
Alves VAF: Histological grading of hepatocellular carcinoma-A
systematic review of literature. Front Med. 4(193)2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Szklaruk J, Silverman PM and Charnsangavej
C: Imaging in the diagnosis, staging, treatment, and surveillance
of hepatocellular carcinoma. AJR Am J Roentgenol. 180:441–454.
2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Elgamal S, Ghafar AA, Ghoneem E, Elshaer
M, Alrefai H and Elemshaty W: Characterization of patients with
hepatocellular carcinoma on the way for early detection: One center
experience. Egypt J Int Med. 30:231–238. 2018.
|
|
23
|
Omar M, Elazab T, Abdelrahman A and
Mohamed E: Clinical significance of serum midkine level as a
biomarker in diagnosis of hepatocellular carcinoma. Benha Med J
(Internal Med Hepatol) Special Issue. 37:37–46. 2020.
|
|
24
|
Fang Y, Sun X, Zhang L, Xu Y and Zhu W:
Hemoglobin/red blood cell distribution width ratio in peripheral
blood is positively associated with prognosis of patients with
primary hepatocellular carcinoma. Med Sci Monit. 28:e937146–1.
2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Newsome PN, Cramb R, Davison SM, Dillon
JF, Foulerton M, Godfrey EM, Hall R, Harrower U, Hudson M, Langford
A, et al: Guidelines on the management of abnormal liver blood
tests. Gut. 67:6–19. 2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mohamed BF, Serag WM, Abdelal RM and
Elsergany HF: S100A14 protein as diagnostic and prognostic marker
in hepatocellular carcinoma. Egypt Liver J. 9:1–6. 2019.
|
|
27
|
Carr BI and Guerra V: Serum albumin levels
in relation to tumor parameters in hepatocellular carcinoma
patients. Int J Biol Markers. 32:e391–e396. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Nishikawa H, Kita R, Kimura T, Ohara Y,
Sakamoto A, Saito S and Osaki Y: Hyponatremia in hepatocellular
carcinoma complicating with cirrhosis. J Cancer. 6:482–489.
2015.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Guerra Ruiz AR, Crespo J, LópezMartínez
RM, Iruzubieta P, Casals Mercadal G, Lalana Garcés M and Morales
Ruiz M: Measurement and clinical usefulness of bilirubin in liver
disease. Adv Lab Med. 2:352–361. 2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Watanabe M, Yokomori H, Takahashi Y, Okada
T, Shibuya A and Koizumi W: Assessing the characteristics and
feasibility of preventing early mortality in patients with
hepatocellular carcinoma. The Turkish J Gastroenterol. 30:541–548.
2019.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Singh Y, Nagar D, Singh M and Maroof M:
Study of electrolyte disturbance in chronic liver disease patients
attending a hospital in Kumaon region. J Family Med Primary Care.
11:4479–4482. 2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Zhang J, Chen G, Zhang P, Zhang J, Li X,
Gan DN and Ye YA: The threshold of alpha-fetoprotein (AFP) for the
diagnosis of hepatocellular carcinoma: A systematic review and
meta-analysis. PLoS One. 15(e0228857)2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chen W, Wang W, Zhou L, Zhou J, He L, Li
J, Xu X, Wang J and Wang L: Elevated AST/ALT ratio is associated
with all-cause mortality and cancer incident. J Clin Lab Anal.
36(e24356)2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Zhang H, Gao C, Fang L and Yao SK:
Increased international normalized ratio level in hepatocellular
carcinoma patients with diabetes mellitus. World J Gastroenterol.
19:2395–2403. 2013.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang SH, Cong WM, Xian ZH, Dong H and Wu
MC: Genomic instability in hepatocellular carcinoma revealed by
using the random amplified polymorphic DNA method. J Cancer Res
Clin Oncol. 130:757–761. 2004.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chariyalertsak S, Khuhaprema T,
Bhudisawasdi V, Sripa B, Wongkham S and Petmitr S: Novel DNA
amplification on chromosomes 2p25.3 and 7q11.23 in
cholangiocarcinoma identified by arbitrarily primed polymerase
chain reaction. J Cancer Res Clin Oncol. 131:821–828.
2005.PubMed/NCBI View Article : Google Scholar
|
